Artem Voloskovets
Hims & Hers Health has had a rough few months. The stock has lost more than half its value from recent highs, dropping well below earlier downside targets and landing near $16. Now, with earnings on the horizon, the question isn't about price levels anymore — it's about whether the underlying business can hold up.
What Sent HIMS Stock Tumbling to $16?
The decline didn't happen overnight. The move toward $25 played out first, but a combination of regulatory pressure and legal developments pushed the stock further down to around $16. The selling was relentless, mirroring previous extended downtrend phases Hims & Hers slides toward $28 support where the company struggled to find its footing.
"Attention has shifted away from price targets and toward the broader business thesis." — StockChaser
With the stock trading near multi-month lows, technical analysts have been eyeing critical support zones between $15 and $13.60 — a range that underscores just how sensitive valuations have become at these levels.
Can Earnings Reverse the Trend?
The upcoming Q4 and full-year results will be a defining moment for Hims & Hers. Investors will be focused on three main things: revenue growth momentum, subscriber expansion, and margin structure. Profitability metrics and operating efficiency matter a lot right now — they'll show whether the company can stabilize after a brutal stretch of selling pressure.
Legal clarity is also high on the watchlist. Recent developments rattled sentiment, and any resolution — or escalation — will likely move the stock.
The 2026 guidance may carry the most weight of all. If management can point to a credible path for re-accelerating growth, that could shift the narrative. If not, the selloff may not be over. Either way, the upcoming earnings release is the clearest checkpoint yet for whether this decline reflects temporary noise or a deeper loss of confidence in Hims & Hers' long-term story.
Artem Voloskovets
